Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 14/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.33 |
| ▸ | RXRA | P19793 | 3/20 | 0.31 |
| ▸ | RXRB | P28702 | 3/20 | 0.31 |
| ▸ | RXRG | P48443 | 3/20 | 0.31 |
| ▸ | RARA | P10276 | 2/20 | 0.31 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759481 | 0.88 | PTGS2 (0.37) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6756526 | 0.88 | PTGS2 (0.34) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6755231 | 0.85 | PTGS1 (0.34) | PTGS2PTGS1ALOX5RXRARXRB | |
| SCHEMBL6758654 | 0.85 | PTGS2 (0.34) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6870814 | 0.84 | RXRA (0.32) | PTGS2PTGS1ALOX5RXRARXRB | |
| SCHEMBL6158663 | 0.84 | RXRA (0.32) | PTGS2PTGS1ALOX5RXRARXRB | |
| SCHEMBL6755892 | 0.83 | RXRA (0.31) | PTGS2PTGS1ALOX5RXRARXRB | |
| SCHEMBL6761070 | 0.81 | RXRA (0.30) | PTGS2PTGS1ALOX5RXRARXRB | |
| SCHEMBL6758656 | 0.81 | PTGS2 (0.47) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6157545 | 0.79 | PTGS2 (0.36) | PTGS2PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720423-B2 | SKIN RELATED DISEASES; PROMOTE THE EXPRESSION OF OR BIND TO RECEPTORS BELONGING TO THE STEROID OR THYROID RECEPTOR SUPERFAMILY. | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | RXRB, RXRA, RXRG | PTGS2 1241/4885PTGS1 973/4885ALOX5 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.